Please enable JavaScript to continue using this application.

Compare $ACET vs $XLO | Chartloom

Compare

$ACET vs $XLO

Adicet Bio Inc · Xilio Therapeutics Inc

ACET

Adicet Bio Inc

XLO

Xilio Therapeutics Inc

Compare $ACET vs $XLO

Comparing Adicet Bio Inc and Xilio Therapeutics Inc

ACETAdicet Bio Inc

XLOXilio Therapeutics Inc

ACETAdicet Bio Inc

Market cap

$52M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

-36.4%

52W performance

-62.2%

FCF yield

-162.0%

XLOXilio Therapeutics Inc

Market cap

$54M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

3.42x

Rev growth (TTM)

327.3%

YTD performance

-3.8%

52W performance

-23.1%

FCF yield

-113.2%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

ACET

XLO

Detailed metrics comparison

ACET

Adicet Bio Inc

XLO

Xilio Therapeutics Inc

Market Cap

ACET$52M

XLO$54M

Enterprise Value

ACET$20M

XLO$-82M

Price

ACET$5.61

XLO$9.05

P/E Ratio

ACETN/A

XLON/A

P/S Ratio

ACET1.57x

XLO0.84x

EV/Sales

ACET0.74x

XLO-1.28x

EV/EBITDA

ACET0.00x

XLO0.00x

P/B Ratio

ACET0.51x

XLO0.82x

P/FCF Ratio

ACETN/A

XLON/A

EV/FCF

ACET-0.24x

XLO1.34x

PEG Ratio

ACETN/A

XLON/A

Forward P/E (NTM)

ACETN/A

XLON/A

Forward P/S (NTM)

ACETN/A

XLO3.42x

Revenue (TTM)

ACET$0

XLO$64M

Revenue Growth (YoY)

ACETN/A

XLO327.3%

Forward Rev Growth

ACET171.3%

XLO-34.2%

Gross Margin (TTM)

ACET0.0%

XLO0.0%

Operating Margin (TTM)

ACET0.0%

XLO0.0%

EBITDA Margin (TTM)

ACET0.0%

XLO-46.9%

Net Margin (TTM)

ACET0.0%

XLO-34.1%

FCF Margin (TTM)

ACETN/A

XLO-95.6%

Net Income (TTM)

ACET$-99M

XLO$-22M

FCF (TTM)

ACET$-85M

XLO$-61M

EPS (TTM)

ACET-$9.21

XLO-$1.12

ROE (TTM)

ACET-7490.0%

XLO-923.0%

ROA (TTM)

ACET-6087.0%

XLO-1441.0%

ROIC (TTM)

ACET-7437.0%

XLO-923.0%

Cash

ACET$33M

XLO$136M

Debt

ACET$798K

XLO$0

Net Cash/Debt

ACET$32M

XLO$136M

Current Ratio (TTM)

ACET6.71x

XLO4.25x

Quick Ratio (TTM)

ACET6.59x

XLO4.15x

Debt/Equity (TTM)

ACET0.01x

XLO0.00x

Debt/Assets (TTM)

ACET0.0%

XLO0.0%

Interest Coverage (TTM)

ACETN/A

XLON/A

Net Debt/EBITDA (TTM)

ACET0.00x

XLO0.00x

Beta

ACET1.68

XLO-0.12

52W Performance

ACET-62.2%

XLO-23.1%

YTD Performance

ACET-36.4%

XLO-3.8%

% from 52W High

ACET-67.8%

XLO-28.1%

% from 52W Low

ACET1.1%

XLO40.0%

Asset Turnover (TTM)

ACET0.13x

XLO0.42x

FCF Yield (TTM)

ACET-162.0%

XLO-113.2%

Earnings Yield (TTM)

ACET-188.7%

XLO-40.3%

Dividend Yield (TTM)

ACETN/A

XLON/A

Rule of 40

ACET0.0

XLO231.7

EV/GP/RG

ACETN/A

XLON/A

Ticker research

View ACET research View XLO research

Metric	ACET Adicet Bio Inc	XLO Xilio Therapeutics Inc
Market & Valuation
Market Cap	$52M	$54M
Enterprise Value	$20M	$-82M
Price	$5.61	$9.05
P/E Ratio	N/A	N/A
P/S Ratio	1.57x	0.84x
EV/Sales	0.74x	-1.28x
EV/EBITDA	0.00x	0.00x
P/B Ratio	0.51x	0.82x
P/FCF Ratio	N/A	N/A
EV/FCF	-0.24x	1.34x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	3.42x
Revenue & Growth
Revenue (TTM)	$0	$64M
Revenue Growth (YoY)	N/A	327.3%
Forward Rev Growth	171.3%	-34.2%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	-46.9%
Net Margin (TTM)	0.0%	-34.1%
FCF Margin (TTM)	N/A	-95.6%
Net Income (TTM)	$-99M	$-22M
FCF (TTM)	$-85M	$-61M
EPS (TTM)	-$9.21	-$1.12
ROE (TTM)	-7490.0%	-923.0%
ROA (TTM)	-6087.0%	-1441.0%
ROIC (TTM)	-7437.0%	-923.0%
Financial Health
Cash	$33M	$136M
Debt	$798K	$0
Net Cash/Debt	$32M	$136M
Current Ratio (TTM)	6.71x	4.25x
Quick Ratio (TTM)	6.59x	4.15x
Debt/Equity (TTM)	0.01x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.68	-0.12
52W Performance	-62.2%	-23.1%
YTD Performance	-36.4%	-3.8%
% from 52W High	-67.8%	-28.1%
% from 52W Low	1.1%	40.0%
Efficiency & Yields
Asset Turnover (TTM)	0.13x	0.42x
FCF Yield (TTM)	-162.0%	-113.2%
Earnings Yield (TTM)	-188.7%	-40.3%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	231.7
EV/GP/RG	N/A	N/A
Ticker research	View ACET research	View XLO research

Valuation

P/S Ratio

XLO

0.84x

ACET

1.57x

EV/FCF

ACET

-0.24x

XLO

1.34x

Growth & revenue

Revenue Growth TTM

XLO

327.3%

Forward Revenue Growth

ACET

171.3%

XLO

-34.2%

Profitability & performance

Gross Margin

ACET

0.0%

XLO

0.0%

ROE

XLO

-923.0%

ACET

-7490.0%

FCF Yield %

XLO

-113.2%

ACET

-162.0%

52-Week Performance

XLO

-23.1%

ACET

-62.2%

Detailed metrics comparison

ACET

Adicet Bio Inc

XLO

Xilio Therapeutics Inc

Market Cap

ACET$52M

XLO$54M

Enterprise Value

ACET$20M

XLO$-82M

Price

ACET$5.61

XLO$9.05

P/E Ratio

ACETN/A

XLON/A

P/S Ratio

ACET1.57x

XLO0.84x

EV/Sales

ACET0.74x

XLO-1.28x

EV/EBITDA

ACET0.00x

XLO0.00x

P/B Ratio

ACET0.51x

XLO0.82x

P/FCF Ratio

ACETN/A

XLON/A

EV/FCF

ACET-0.24x

XLO1.34x

PEG Ratio

ACETN/A

XLON/A

Forward P/E (NTM)

ACETN/A

XLON/A

Forward P/S (NTM)

ACETN/A

XLO3.42x

Revenue (TTM)

ACET$0

XLO$64M

Revenue Growth (YoY)

ACETN/A

XLO327.3%

Forward Rev Growth

ACET171.3%

XLO-34.2%

Gross Margin (TTM)

ACET0.0%

XLO0.0%

Operating Margin (TTM)

ACET0.0%

XLO0.0%

EBITDA Margin (TTM)

ACET0.0%

XLO-46.9%

Net Margin (TTM)

ACET0.0%

XLO-34.1%

FCF Margin (TTM)

ACETN/A

XLO-95.6%

Net Income (TTM)

ACET$-99M

XLO$-22M

FCF (TTM)

ACET$-85M

XLO$-61M

EPS (TTM)

ACET-$9.21

XLO-$1.12

ROE (TTM)

ACET-7490.0%

XLO-923.0%

ROA (TTM)

ACET-6087.0%

XLO-1441.0%

ROIC (TTM)

ACET-7437.0%

XLO-923.0%

Cash

ACET$33M

XLO$136M

Debt

ACET$798K

XLO$0

Net Cash/Debt

ACET$32M

XLO$136M

Current Ratio (TTM)

ACET6.71x

XLO4.25x

Quick Ratio (TTM)

ACET6.59x

XLO4.15x

Debt/Equity (TTM)

ACET0.01x

XLO0.00x

Debt/Assets (TTM)

ACET0.0%

XLO0.0%

Interest Coverage (TTM)

ACETN/A

XLON/A

Net Debt/EBITDA (TTM)

ACET0.00x

XLO0.00x

Beta

ACET1.68

XLO-0.12

52W Performance

ACET-62.2%

XLO-23.1%

YTD Performance

ACET-36.4%

XLO-3.8%

% from 52W High

ACET-67.8%

XLO-28.1%

% from 52W Low

ACET1.1%

XLO40.0%

Asset Turnover (TTM)

ACET0.13x

XLO0.42x

FCF Yield (TTM)

ACET-162.0%

XLO-113.2%

Earnings Yield (TTM)

ACET-188.7%

XLO-40.3%

Dividend Yield (TTM)

ACETN/A

XLON/A

Rule of 40

ACET0.0

XLO231.7

EV/GP/RG

ACETN/A

XLON/A

Ticker research

View ACET research View XLO research

Metric	ACET Adicet Bio Inc	XLO Xilio Therapeutics Inc
Market & Valuation
Market Cap	$52M	$54M
Enterprise Value	$20M	$-82M
Price	$5.61	$9.05
P/E Ratio	N/A	N/A
P/S Ratio	1.57x	0.84x
EV/Sales	0.74x	-1.28x
EV/EBITDA	0.00x	0.00x
P/B Ratio	0.51x	0.82x
P/FCF Ratio	N/A	N/A
EV/FCF	-0.24x	1.34x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	3.42x
Revenue & Growth
Revenue (TTM)	$0	$64M
Revenue Growth (YoY)	N/A	327.3%
Forward Rev Growth	171.3%	-34.2%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	-46.9%
Net Margin (TTM)	0.0%	-34.1%
FCF Margin (TTM)	N/A	-95.6%
Net Income (TTM)	$-99M	$-22M
FCF (TTM)	$-85M	$-61M
EPS (TTM)	-$9.21	-$1.12
ROE (TTM)	-7490.0%	-923.0%
ROA (TTM)	-6087.0%	-1441.0%
ROIC (TTM)	-7437.0%	-923.0%
Financial Health
Cash	$33M	$136M
Debt	$798K	$0
Net Cash/Debt	$32M	$136M
Current Ratio (TTM)	6.71x	4.25x
Quick Ratio (TTM)	6.59x	4.15x
Debt/Equity (TTM)	0.01x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.68	-0.12
52W Performance	-62.2%	-23.1%
YTD Performance	-36.4%	-3.8%
% from 52W High	-67.8%	-28.1%
% from 52W Low	1.1%	40.0%
Efficiency & Yields
Asset Turnover (TTM)	0.13x	0.42x
FCF Yield (TTM)	-162.0%	-113.2%
Earnings Yield (TTM)	-188.7%	-40.3%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	231.7
EV/GP/RG	N/A	N/A
Ticker research	View ACET research	View XLO research